Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSLI-RTU vs Marqibo in Hematological Malignancies
NCT04243434Phase 1Unknown
- Sponsor
- Acrotech Biopharma Inc
- Start
- Aug 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules, Lipid-based Nanoparticles
01
Overview
Phase 1, randomised, open-label trial of vincristine sulfate liposome in hematologic malignancy (2 cohorts), sponsored by Acrotech Biopharma Inc. Primary endpoint: Area under the concentration time curve at 6 weeks. Status: unknown.
02
Drugs
vincristine sulfate liposome
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04243434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243434.